Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice - PubMed (original) (raw)
. 2010 Jul;120(7):2627-34.
doi: 10.1172/JCI42304. Epub 2010 Jun 23.
Moritz Wildgruber, Takuya Ueno, Jose-Luiz Figueiredo, Peter Panizzi, Yoshiko Iwamoto, Elizabeth Zhang, James R Stone, Elisenda Rodriguez, John W Chen, Mikael J Pittet, Ralph Weissleder, Matthias Nahrendorf
Affiliations
- PMID: 20577051
- PMCID: PMC2898607
- DOI: 10.1172/JCI42304
Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice
Filip K Swirski et al. J Clin Invest. 2010 Jul.
Abstract
Rates of graft rejection are high among recipients of heart transplants. The onset and progression of clinically significant heart transplant rejection are currently monitored by serial biopsy, but this approach is highly invasive and lacks sensitivity. Here, we have developed what we believe to be a new technique to measure organ rejection noninvasively that involves the exploration of tissue-infiltrating leukocytes as biomarker sources for diagnostic imaging. Specifically, we profiled the myeloid response in a murine model of heart transplantation with the aim of defining and validating an imaging signature of graft rejection. Ly-6Chi monocytes, which promote inflammation, accumulated progressively in allografts but only transiently in isografts. Ly-6Clo monocytes, which help resolve inflammation, did not accumulate, although they composed the majority of the few remaining monocytes in isografts. The persistence of Ly-6Chi monocytes in allografts prompted us to screen for a Ly-6Chi monocyte-associated imaging marker. Low-density array data revealed that Ly-6Chi monocytes express 10-fold higher levels of myeloperoxidase (MPO) than Ly-6Clo monocytes. Noninvasive magnetic resonance imaging of MPO with an MPO-activatable Gd-chelate revealed a spatially defined T1-weighted signal in rejected allografts but not in isografts or MPO-deficient allograft recipients. Flow cytometry, enzymography, and histology validated the approach by mapping MPO activity to Ly-6Chi monocytes and neutrophils. Thus, MPO imaging represents a potential alternative to the current invasive clinical standard by which transplants are monitored.
Figures
Figure 1. Myeloid cell profile in transplant rejection.
(A) Flow cytometric analysis of cell suspensions retrieved from native hearts and iso- and allografted hearts 7 days after transplantation. Lin, CD90/B220/CD49b/NK1.1/Ly-6G. Histograms on right depict the level of Ly-6C expression in respective populations. A representative experiment of 5 is shown. Tx, transplantation. (B) Time course of myeloid cell presence in heart and blood of allograft (black circles) and isograft (white circles) recipients. Animals receiving no transplants served as controls. (C) Ratio of Ly-6Chi vs. Ly-6Clo monocytes in the native heart, in isografts and allografts, and in blood. Data are shown as mean ± SEM; n = 3–5 per group.
Figure 2. MPO levels in leukocytes retrieved from blood and transplants.
(A) Flow cytometric intracellular MPO staining on lymphocytes, neutrophils, Ly-6Chi monocytes, and Ly-6Clo monocytes. 1 of 3 representative experiments is shown. Numbers indicate percentage of cells in respective gates. (B) Relative contribution of leukocytes to overall MPO expression in allografts and isografts. The area of the pie chart reflects overall MPO content per mg tissue, which is the product of per cell MPO content and the abundance of each cell type in the heart, as determined by flow cytometry. (C) MPO activity (n = 3) of lysed sorted leukocytes.
Figure 3. MRI of MPO activity.
(A and B) Orientation of the heterotopic graft and localizer MRI. (C) Change of CNR from before to 2 hours after MPO-Gd injection in wild-type and MPO-deficient mice 7 days after allograft transplantation. Data are shown as mean ± SEM; n = 4–9 per group; *P = 0.02. (D and E) Representative short axis views of allografts 2 hours after injection of MPO-Gd.
Figure 4. Kinetics and distribution of enhancement.
(A and B) T1-weighted short axis MRI of allo- and isografts 7 days after transplantation before and up to 120 minutes after injection of MPO-Gd. Circles indicate location of heart grafts. Data are shown as mean ± SEM; n = 6 per group. (C) Magnified MR image of isograft 120 minutes after injection of MPO-Gd. Some focal bright signal reflects spin refreshment effects due to blood flow. Scale bars: 1 mm. (D) Allograft 120 minutes after injection of MPO-Gd. (E) Same data as in D, but the MPO-Gd signal was thresholded and pseudocolored in red. (F) Immunoreactive staining for MPO in the area that enhances in D and E. Scale bar: 20 μm. (G) Thresholded data of signal enhancement 120 minutes after injection of MPO-Gd show typical enhancement patterns. To highlight the more comprehensive sampling of imaging over the clinical standard, areas that would be accessible to heart biopsies, which are routinely taken from the right ventricular cavity, are color-coded in yellow. Red encodes foci of rejection that could not be reached with routine transvenous right ventricular biopsies.
Figure 5. Effects of clinically relevant immunosuppressive therapy 7 days after transplantation.
(A) MPO protein tissue level assessed by Western blotting and (B) biochemical determination of MPO tissue activity in isografts, allografts, and allografts of mice treated with prednisolone, azathioprine, and cyclosporine (Rx). (A) Data are shown as mean ± SEM; n = 3 per group. *P < 0.01 (C) Flow cytometric profiling of leukocytes in the same groups as above. (D and E) Quantitative immunoreactive staining for MPO, Ly-6C, macrophage (F4/80), and neutrophil marker (NIMP-R14) in the 3 groups. n = 3 mice per group, *P < 0.01. Scale bar: 10 μm. (F) Representative MPO-Gd MRI before and 120 minutes after injection. Circles indicate graft. Next to the graft, the bladder showed enhancement, indicating renal excretion of MPO-Gd. No enhancement was seen in the allograft treated with immunosuppressive therapy. (G) Change of CNR before injection versus 2 hours after injection in iso- and allografts of mice with and without treatment. n = 6 per group, *P < 0.05.
Figure 6. MPO-targeted MRI detects subtle transplant rejection.
(A) MR images acquired 2 hours after MPO-Gd in various groups and time points, H&E histology, and CD11b immunoreactive staining for myeloid cells and H&E histology. Scale bar: 25 μm. Arrows indicate enhancing regions after injection of MPO-Gd. (B) MR data acquired in mice treated with insufficient immunosuppression on day 7 after allograft. Pred, prednisolone. n = 4–6 per group. *P < 0.05 versus iso- and untreated allograft. (C) Serial imaging in isograft controls (n = 4) and single MHC class II mismatch (Bm12→B6, n = 7, *P < 0.05).
Figure 7. Translational potential of MPO as an imaging target for organ rejection.
(A) MPO protein levels measured by flow cytometry in human blood monocyte subsets. (B) MPO in biopsy samples from patients after heart transplantation. H&E stain and immunoreactive staining for MPO in representative sections from patient biopsies. Patient on left had no signs of rejection (grade 0) and no MPO+ cells, whereas patient on the right was graded 3R (severe rejection/high grade infiltrate) and showed MPO+ cells on immunoreactive staining. Scale bar: 20 μm. (C) Quantification of MPO+ cells in patients with no (ISHLT grade 0), mild (1R), and high grade (2/3R) cellular infiltration. Data are shown as mean ± SEM.
Similar articles
- Molecular imaging of innate immune cell function in transplant rejection.
Christen T, Nahrendorf M, Wildgruber M, Swirski FK, Aikawa E, Waterman P, Shimizu K, Weissleder R, Libby P. Christen T, et al. Circulation. 2009 Apr 14;119(14):1925-32. doi: 10.1161/CIRCULATIONAHA.108.796888. Epub 2009 Mar 30. Circulation. 2009. PMID: 19332470 Free PMC article. - Recipient myeloperoxidase-producing cells regulate antibody-mediated acute versus chronic kidney allograft rejection.
Miyairi S, Ueda D, Yagisawa T, Okada D, Keslar KS, Tanabe K, Dvorina N, Valujskikh A, Baldwin WM 3rd, Hazen SL, Fairchild RL. Miyairi S, et al. JCI Insight. 2021 Jul 8;6(13):e148747. doi: 10.1172/jci.insight.148747. JCI Insight. 2021. PMID: 34081629 Free PMC article. - P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice.
An G, Wang H, Tang R, Yago T, McDaniel JM, McGee S, Huo Y, Xia L. An G, et al. Circulation. 2008 Jun 24;117(25):3227-37. doi: 10.1161/CIRCULATIONAHA.108.771048. Epub 2008 Jun 2. Circulation. 2008. PMID: 18519846 Free PMC article. - Chronic rejection of organ allografts may arise from injuries sustained in recurring foci of acute rejection that resolve spontaneously.
Lowry RP, Takeuchi T, Cremisi H, Konieczny B, Someren A. Lowry RP, et al. Transplant Proc. 1993 Apr;25(2):2103-5. Transplant Proc. 1993. PMID: 8470286 Review. No abstract available. - Mechanisms involved in antibody- and complement-mediated allograft rejection.
Wasowska BA. Wasowska BA. Immunol Res. 2010 Jul;47(1-3):25-44. doi: 10.1007/s12026-009-8136-3. Immunol Res. 2010. PMID: 20135240 Free PMC article. Review.
Cited by
- CD115+ monocytes protect microbially experienced mice against _E. coli_-induced sepsis.
Martin MD, Skon-Hegg C, Kim CY, Xu J, Kucaba TA, Swanson W, Pierson MJ, Williams JW, Badovinac VP, Shen SS, Ingersoll MA, Griffith TS. Martin MD, et al. Cell Rep. 2023 Nov 28;42(11):113345. doi: 10.1016/j.celrep.2023.113345. Epub 2023 Oct 28. Cell Rep. 2023. PMID: 38111515 Free PMC article. - Hypoxia exacerbates intestinal injury and inflammatory response mediated by myeloperoxidase during Salmonella Typhimurium infection in mice.
Zhu Q, Han Y, Wang X, Jia R, Zhang J, Liu M, Zhang W. Zhu Q, et al. Gut Pathog. 2023 Nov 30;15(1):62. doi: 10.1186/s13099-023-00586-5. Gut Pathog. 2023. PMID: 38037141 Free PMC article. - Myeloperoxidase PET Imaging Tracks Intracellular and Extracellular Treatment Changes in Experimental Myocardial Infarction.
Zeller MWG, Wang C, Keliher EJ, Wojtkiewicz GR, Aguirre A, Maresca K, Su C, Buckbinder L, Wang J, Nahrendorf M, Chen JW. Zeller MWG, et al. Int J Mol Sci. 2023 Mar 16;24(6):5704. doi: 10.3390/ijms24065704. Int J Mol Sci. 2023. PMID: 36982778 Free PMC article. - Role of leukotriene B4 (LTB4)-LTB4 receptor 1 signaling in post-incisional nociceptive sensitization and local inflammation in mice.
Asahara M, Ito N, Hoshino Y, Sasaki T, Yokomizo T, Nakamura M, Shimizu T, Yamada Y. Asahara M, et al. PLoS One. 2022 Oct 20;17(10):e0276135. doi: 10.1371/journal.pone.0276135. eCollection 2022. PLoS One. 2022. PMID: 36264904 Free PMC article. - Molecular Signature of Antibody-Mediated Chronic Vasculopathy in Heart Allografts in a Novel Mouse Model.
Tsuda H, Dvorina N, Keslar KS, Nevarez-Mejia J, Valenzuela NM, Reed EF, Fairchild RL, Baldwin WM 3rd. Tsuda H, et al. Am J Pathol. 2022 Jul;192(7):1053-1065. doi: 10.1016/j.ajpath.2022.04.003. Epub 2022 Apr 29. Am J Pathol. 2022. PMID: 35490714 Free PMC article.
References
- Miniati DN, Robbins RC. Heart transplantation: a thirty-year perspective. Annu Rev Med. 2002;53:189–205. - PubMed
- Kubo SH, et al. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. J Heart Lung Transplant. 1995;14(3):409–418. - PubMed
- Tucker PA 2nd, Jin BS, Gaos CM, Radovancevic B, Frazier OH, Wilansky S. Flail tricuspid leaflet after multiple biopsies following orthotopic heart transplantation: echocardiographic and hemodynamic correlation. J Heart Lung Transplant. 1994;13(3):466–472. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL095612/HL/NHLBI NIH HHS/United States
- U24 CA092782/CA/NCI NIH HHS/United States
- U01 HL080731/HL/NHLBI NIH HHS/United States
- R01HL095629/HL/NHLBI NIH HHS/United States
- R00 HL094533/HL/NHLBI NIH HHS/United States
- R01 NS070835/NS/NINDS NIH HHS/United States
- U01-HL080731/HL/NHLBI NIH HHS/United States
- R01 HL096576/HL/NHLBI NIH HHS/United States
- R01 HL095629/HL/NHLBI NIH HHS/United States
- K08HL081170/HL/NHLBI NIH HHS/United States
- K08 HL081170/HL/NHLBI NIH HHS/United States
- R01 NS072167/NS/NINDS NIH HHS/United States
- U24-CA092782/CA/NCI NIH HHS/United States
- R01 AI084880/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous